QA2020-102 - Data for MPE
Atribute | Detail |
---|---|
Resolution Reporting Subject Matter | Guidance |
Guidance Documents | Additional-LDR |
Taxonomy | - |
Unique Identifier |
QA2020-102 |
Question
How is Template 5 "Data for MPE" (to be submitted with the present MPE strategy) to be filled? Either a description of the relationships between the Resolution Groups or a description of the relationships between any parent companies and the Resolution Groups.Example: Resolution Group A consists of company 1 (point of entry) and company 2 (resolution group entity). Resolution Group B consists exclusively of company 3 (point of entry). Resolution Group A fills Template 5 as follows:- Template 5: Rows 0100-0490 Company data 3- Lines 0500-0690 Capital shares/receivables/RWA of the Companies 1 and 2 an/gg. companies 3 (EUR)-Lines 0700-1000 Percentage share of Capital shares/receivables/RWA etc. of the companies 1 and 2 an/gg. companies 3 (in %)
Response
Please refer to the instructions to the MPE tab in the "Guidance to the Additional Liability Report".
The requested data points refer to instruments issued by the entities in a given Resolution Group and held by entities in the reporting Resolution Group.
- Rows 100 to 490: information from the point of view of the subsidiary Resolution Group at a sub-consolidated level (Company 3). Own Funds and Eligible Liabilities of that Resolution Group.
- Rows 500 to 690: information on interconnections of Own Funds and Eligible Liabilities from all entities of the reporting Resolution Group to all entities of the other Resolution Groups. Information to be reported from the point of view of the reporting Resolution Group, based on book value of its assets.
Related articles
-
-
QA2025-12- Due date for reporting of MREL TLAC Q1 2025 (Questions and Answers)
-
-
-
-
-
QA2024-23 - FMIR T33.00 c0090 Value of transactions on proprietary accounts (Questions and Answers)
-
QA2024-16 - ECB Market Data for Payments to MFIs and Non-MFIs (Questions and Answers)
-
-
-
-
-
-
-
QA2023-23 - Should Transfer Agents be reported in the FMIR? (Questions and Answers)